Muñoz-Galván, Sandra <br/><br/>
PAI1 is a Marker of Bad Prognosis in Rectal Cancer but Predicts a Better Response to Treatment with PIM Inhibitor AZD1208.  [electronic resource] 

 -  Cells  04 2020 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2073-4409 
<br/><br/><label>Standard No.: </label>10.3390/cells9051071  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Apoptosis--drug effects<br/>Biomarkers, Pharmacological<br/>Biomarkers, Tumor<br/>Biphenyl Compounds--pharmacology<br/>Cell Line, Tumor<br/>Cell Proliferation--drug effects<br/>Cell Survival--drug effects<br/>Colorectal Neoplasms--drug therapy<br/>Female<br/>Humans<br/>Male<br/>Middle Aged<br/>Neoplasm Recurrence, Local--drug therapy<br/>Plasminogen Activator Inhibitor 1--metabolism<br/>Prognosis<br/>Protein Kinase Inhibitors<br/>Protein Serine-Threonine Kinases--metabolism<br/>Rectal Neoplasms--drug therapy<br/>Thiazolidines--pharmacology